Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02989584 · ClinicalTrials.gov registry record · Phase 1

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

A Phase 1 study of Bladder Cancer and Urothelial Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
54
Enrollment target
11
Study locations

NCT02989584 is a Phase 1 study of Bladder Cancer and Urothelial Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 11 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02989584, a Phase 1 study of Bladder Cancer and Urothelial Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
54 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to test the safety of the study drug, atezolizumab, when combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC). This study will help researchers begin to understand whether combining GC with atezolizumab is better, the same, or worse than the usual approach of using GC alone.

Conditions Studied

Bladder Cancer Urothelial Carcinoma Metastatic Bladder Cancer

Interventions

  • DRUG Atezolizumab
  • DRUG Cisplatin
  • DRUG Gemcitabine

Study Locations (11)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • New York University - New York
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Connecticut

  • Hartford Healthcare Cancer Institute @ Hartford Hospital - Hartford

Ohio

  • Ohio State University - Columbus

Pennsylvania

  • Lehigh Valley Health Network - Allentown

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2016-12-20
Est. Completion 2026-12
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02989584

The ClinicalTrials.gov registry entry for NCT02989584 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT02989584 reports 11 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02989584 about?

NCT02989584 is a clinical study titled "A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer". The purpose of this study is to test the safety of the study drug, atezolizumab, when combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC). This study will help researchers begin to understand whether combining GC with atezolizumab is better, the same, or worse than the u...

What is the current status of trial NCT02989584?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2016-12-20. Estimated completion is 2026-12.

What conditions does trial NCT02989584 study?

This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Metastatic Bladder Cancer.

What interventions are being tested in trial NCT02989584?

The interventions under investigation include: Atezolizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG).

Who is sponsoring clinical trial NCT02989584?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02989584 being conducted?

This trial has 11 study locations across Connecticut, New Jersey, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Bladder Cancer

All registered trials for this condition

Urothelial Carcinoma

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.